EP Patent

EP2120578A1 — Kinase inhibitor compounds

Assigned to Tyrogenex Inc · Expires 2009-11-25 · 16y expired

What this patent protects

Pyridine and pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

USPTO Abstract

Pyridine and pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases and are useful in treating disorders related to abnormal protein kinase activities such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2120578A1
Jurisdiction
EP
Classification
—
Expires
2009-11-25
Drug substance claim
No
Drug product claim
No
Assignee
Tyrogenex Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.